-

Innovaderm Research Rebrands as Indero, a Dual-Focus CRO

MONTREAL--(BUSINESS WIRE)--Innovaderm, a leading clinical research organization (CRO), is excited to reveal a major rebranding to Indero, with immediate effect. The new brand identity reinforces the company’s dual focus on rheumatology and dermatology and recognizes the close synergy between these fields.

Innovaderm has over 25 years of clinical research experience within dermatology, and recognizes that many inflammatory and autoimmune conditions manifest across both the skin and the musculoskeletal system. Rheumatology and dermatology therefore often overlap in diagnosing and managing diseases where the immune system plays a central role, and Indero will harness its expertise to deliver comprehensive, patient-focused solutions for these markets. The company’s full-service approach can support both early and late-phase trials across both specialties.

Dr Robert Bissonnette, Founder and Executive Chairman, commented: “As Innovaderm, we have served the dermatology clinical research community for 25 years, building a reputation for quality and excellence. As we move forward as Indero, we will continue to provide the expertise in dermatology that our clients have come to expect from us, while further strengthening our focus on rheumatology and expanding our support within this field. We are excited about the future and supporting the development of new therapies in these two areas of research, ultimately helping to improve patients' health and quality of life.”

Jeff Smith, CEO of Indero, added: “Our dual-focus, interdisciplinary approach allows us to support clinical studies for a wide range of rheumatology and dermatology conditions. The immune-mediated nature of both disease areas means that we are perfectly positioned to support clinical research across these specialties. Our network of investigators and research sites – combined with extensive in-house experience – means that we can support sponsors with the unique requirements of trials in these fields, from difficult-to-find patient populations to complex endpoints. As Indero, we are ‘all in’ with our commitment to providing sponsors with the rigorous scientific foundation and tailored expertise that their studies need.”

Visit www.inderocro.com to explore Indero’s services and expertise.

About Indero

Indero is a dual-focus CRO for dermatology and rheumatology, with over 25 years of experience in clinical research and trial delivery. Our full-service approach – which includes everything from protocol design and patient recruitment to trial monitoring and biometrics – provides biotech and pharmaceutical sponsors with the rigorous scientific foundation and tailored expertise their studies need to reach the finish line efficiently and effectively. With capabilities in the U.S., Canada, Europe, LATAM, and APAC; vast, continuously growing relationships with investigators and patients; and a dedicated research clinic through which we design and execute our own studies, Indero is the ideal partner for clinical needs at global scale.

Contacts

For more information:
Valerie Coveney
Communications Specialist
Indero
vcoveney@inderocro.com

Indero



Contacts

For more information:
Valerie Coveney
Communications Specialist
Indero
vcoveney@inderocro.com

More News From Indero

Indero Announces Breakthrough Method for Early-Phase Evaluation of Topical Drugs Using Quantitative Gene Expression

MONTREAL--(BUSINESS WIRE)--Indero is proud to announce the successful completion of an internally funded study that introduces a novel approach to evaluating topical new chemical entities (NCE) in early-phase clinical research. This innovative method leverages quantitative gene expression analysis to assess drug efficacy rapidly and cost effectively. Dr. Robert Bissonnette, Executive Chairman and Founder of Indero, who initiated and led the study, shared his excitement about the results: “Our g...

Indero Celebrates 25 Years and Looks to the Future of Clinical Research

MONTREAL--(BUSINESS WIRE)--Indero, the niche CRO formerly known as Innovaderm, is celebrating 25 years of advancing clinical research. From its roots as a dermatology site in Montreal, Indero has grown into a global organization with capabilities in more than 30 countries across 4 continents and has earned a reputation for delivering expert, efficient trials in dermatology and, more recently, rheumatology. Indero was founded as Innovaderm in 2000, starting as a clinical site and now a global CR...

Innovaderm Research, a Dual Focus CRO, Appoints Jeff Smith as New CEO

MONTREAL--(BUSINESS WIRE)--Innovaderm Research, a leader in dermatological and rheumatological research, is proud to announce the appointment of Jeff Smith as the new CEO of the organization. This strategic change allows Innovaderm’s founder and former CEO, Dr. Robert Bissonnette, to fully dedicate himself to his role as Executive Chairman of Innovaderm, providing medical and scientific support to the CRO and its clients. Jeff brings nearly 30 years of experience in the pharmaceutical and CRO i...
Back to Newsroom